Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01418313 · ClinicalTrials.gov registry record

Non-Invasive Imaging of Atherosclerosis

A clinical trial of Atherosclerosis, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
886
Enrollment target
1
Study location

NCT01418313: Completed study of Atherosclerosis, sponsored by Icahn School of Medicine at Mount Sinai.

NCT01418313 is a study of Atherosclerosis that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 886 participants, below the 1,053-participant average among 69 other Atherosclerosis trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01418313, a study of Atherosclerosis, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
886 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to develop and validate novel magnetic resonance imaging (MRI), dynamic contrast enhanced (DCE)-MRI and positron emission tomography (PET)/MR techniques for the detection and risk stratification of patients with atherosclerosis.

Primary Outcome

R correlation coefficient

Conditions Studied

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 886 participants
Start Date 2011-09
Est. Completion 2020-03-09

What the finished NCT01418313 record still lists

NCT01418313 is an observational study that tracks outcomes without assigning an intervention. The registered 886 participants enrollment target is mid-sized for trials with a published cap, below the 1,053-participant average among 69 other Atherosclerosis trials with a reported enrollment target (16% lower).

The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT01418313 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01418313 about?

NCT01418313 is a clinical study titled "Non-Invasive Imaging of Atherosclerosis". The purpose of this study is to develop and validate novel magnetic resonance imaging (MRI), dynamic contrast enhanced (DCE)-MRI and positron emission tomography (PET)/MR techniques for the detection and risk stratification of patients with atherosclerosis.

What is the current status of trial NCT01418313?

This trial is currently completed. The enrollment target is 886 participants. The study started on 2011-09. Estimated completion is 2020-03-09.

What conditions does trial NCT01418313 study?

This clinical trial studies the following conditions: Atherosclerosis.

Who is sponsoring clinical trial NCT01418313?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01418313 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atherosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01418313's enrollment target sits among peer trials

886 17th of 69 higher than 53 of 69 other Atherosclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03564340 · 890 participants · Phase 1

    Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • NCT07196748 · 882 participants · Phase 3

    A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  • NCT05855200 · 892 participants · Phase 3

    Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  • NCT05174286 · 880 participants · NA

    Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01418313, the US trial registry maintained by the National Library of Medicine. NCT01418313 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.